| |
 |
ARTICLES 
|
|
| Prognostic assessment in node-negative breast cancer patients |
| R Holland and AL Verbeek |
|
JCO Sep 1 1990: 1451–1453.
[PDF]
|
 |
| Is portal-vein fluorouracil hepatic infusion effective colon cancer surgical adjuvant therapy? |
| MJ O'Connell |
|
JCO Sep 1 1990: 1454–1456.
[PDF]
|
|
|
Prognostic significance of peritumoral lymphatic and blood vessel invasion in node-negative carcinoma of the breast |
| |
AK Lee, RA DeLellis, ML Silverman, GJ Heatley, and HJ Wolfe |
| |
JCO Sep 1 1990: 1457–1465.
[Abstract]
[PDF]
|
|
|
Adjuvant therapy of Dukes' A, B, and C adenocarcinoma of the colon with portal-vein fluorouracil hepatic infusion: preliminary results of National Surgical Adjuvant Breast and Bowel Project Protocol C-02 |
| |
N Wolmark, H Rockette, DL Wickerham, B Fisher, C Redmond, ER Fisher, M Potvin, RJ Davies, J Jones, and A Robidoux |
| |
JCO Sep 1 1990: 1466–1475.
[Abstract]
[PDF]
|
|
|
Effect of patients' expectations of benefit with standard breast cancer adjuvant chemotherapy on participation in a randomized clinical trial: a clinical vignette study |
| |
JH Fetting, LA Siminoff, S Piantadosi, MD Abeloff, DJ Damron, and AM Sarsfield |
| |
JCO Sep 1 1990: 1476–1482.
[Abstract]
[PDF]
|
|
|
Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15 |
| |
B Fisher, AM Brown, NV Dimitrov, R Poisson, C Redmond, RG Margolese, D Bowman, N Wolmark, DL Wickerham, and CG Kardinal |
| |
JCO Sep 1 1990: 1483–1496.
[Abstract]
[PDF]
|
|
|
Phase II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancer |
| |
PJ O'Dwyer, AR Paul, J Walczak, LM Weiner, S Litwin, and RL Comis |
| |
JCO Sep 1 1990: 1497–1503.
[Abstract]
[PDF]
|
|
|
Circadian-shaped infusions of floxuridine for progressive metastatic renal cell carcinoma |
| |
WJ Hrushesky, R von Roemeling, RM Lanning, and JT Rabatin |
| |
JCO Sep 1 1990: 1504–1513.
[Abstract]
[PDF]
|
|
|
Multimodal therapy for the management of nonpelvic, localized Ewing's sarcoma of bone: intergroup study IESS-II |
| |
EO Burgert, Jr, ME Nesbit, LA Garnsey, EA Gehan, J Herrmann, TJ Vietti, A Cangir, M Tefft, R Evans, and P Thomas |
| |
JCO Sep 1 1990: 1514–1524.
[Abstract]
[PDF]
|
|
|
Severe hepatic toxicity after treatment with vincristine and dactinomycin using single-dose or divided-dose schedules: a report from the National Wilms' Tumor Study |
| |
DM Green, P Norkool, NE Breslow, JZ Finklestein, and GJ D'Angio |
| |
JCO Sep 1 1990: 1525–1530.
[Abstract]
[PDF]
|
|
|
Prevention of cyclophosphamide/cytarabine-induced emesis with ondansetron in children with leukemia |
| |
PA Carden, SL Mitchell, KD Waters, K Tiedemann, and H Ekert |
| |
JCO Sep 1 1990: 1531–1535.
[Abstract]
[PDF]
|
|
|
Radiocurability of microscopic disease in childhood rhabdomyosarcoma with radiation doses less than 4,000 cGy |
| |
L Mandell, F Ghavimi, T Peretz, M LaQuaglia, and P Exelby |
| |
JCO Sep 1 1990: 1536–1542.
[Abstract]
[PDF]
|
|
|
A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma: report of Radiation Therapy Oncology Group 83-11 |
| |
JD Cox, N Azarnia, RW Byhardt, KH Shin, B Emami, and TF Pajak |
| |
JCO Sep 1 1990: 1543–1555.
[Abstract]
[PDF]
|
|
|
A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861 |
| |
J Klastersky, JP Sculier, H Lacroix, G Dabouis, G Bureau, P Libert, M Richez, P Ravez, G Vandermoten, and J Thiriaux |
| |
JCO Sep 1 1990: 1556–1562.
[Abstract]
[PDF]
|
|
|
Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base |
| |
KS Albain, JJ Crowley, M LeBlanc, and RB Livingston |
| |
JCO Sep 1 1990: 1563–1574.
[Abstract]
[PDF]
|
|
|
Chemotherapy is superior to sequential hemibody irradiation for remission consolidation in multiple myeloma: a Southwest Oncology Group study |
| |
SE Salmon, D Tesh, J Crowley, S Saeed, P Finley, MS Milder, LF Hutchins, CA Coltman, Jr, JD Bonnet, and B Cheson |
| |
JCO Sep 1 1990: 1575–1584.
[Abstract]
[PDF]
|
|
|
Modification of cisplatin toxicity with diethyldithiocarbamate |
| |
JM Berry, C Jacobs, B Sikic, J Halsey, and RF Borch |
| |
JCO Sep 1 1990: 1585–1590.
[Abstract]
[PDF]
|
|
|
Prevention of bacteremia attributed to luminal colonization of tunneled central venous catheters with vancomycin-susceptible organisms |
| |
C Schwartz, KJ Henrickson, K Roghmann, and K Powell |
| |
JCO Sep 1 1990: 1591–1597.
[Abstract]
[PDF]
|
|
| Cotswolds modification of the Ann Arbor staging system for Hodgkin's disease |
| CL Olweny |
|
JCO Sep 1 1990: 1598a.
[PDF]
|
|
| Radionuclide targeting of bone metastases: which efficacy? |
| S Leyvraz and P Burckhardt |
|
JCO Sep 1 1990: 1598b–1599.
[PDF]
|
|
| A linear quadratic analysis of differing fractionation schemes for prophylactic cranial irradiation |
| SH Krosnick and DE Wazer |
|
JCO Sep 1 1990: 1599–1600.
[PDF]
|
|
| Successful rechallenge to etoposide after an acute vasomotor response [published erratum appears in J Clin Oncol 1991 Jan;9(1):193] |
| WJ Tester, JB Cohn, PD Fleekop, MS Rabinowitz, and JS Lieberman |
|
JCO Sep 1 1990: 1600–1601.
[PDF]
|
|
